Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

NCT07339839 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV
KRAS G12C

Interventions

DRUG: Glecirasib
DRUG: Ivonescimab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences